News | November 10, 2021
Moderna seeks approval from EMA for its Covid-19 vaccine for children between 6-11 years
The submission is based on Phase 2/3 study of mRNA-1273 in children ages 6 to 11
The submission is based on Phase 2/3 study of mRNA-1273 in children ages 6 to 11
Kymriah, the first-ever FDA-approved CAR-T cell therapy, is currently available in 30 countries in one or more indications
The youngest child in India to survive ECMO after undergoing bone marrow transplant for a rare disease
Second interchangeable biosimilar product approved by agency
_256_384.jpg)
The two doses of Covaxin are likely to be administered to children with a gap of 28 days
The rolling submission to the U.S. FDA will begin in the fourth quarter of this year
The FDA also approved Repatha as an adjunct to other LDL-C lowering therapies for the treatment of homozygous familial hypercholesterolemia (HoFH) for younger pediatric patients
In participants 5 to 11 years of age, the vaccine was safe, well-tolerated and showed robust neutralising antibody responses. Results in children under 5 years of age are expected as soon as later this year
MeMed BV is a first-of-its-kind test that decodes the immune response to accurately distinguish between bacterial or viral infections within minutes
Data show the vaccine regimen induced neutralising antibody responses in nearly all participating adults and children 21 days after the second dose. Adults receiving booster shots two years after the initial vaccination regimen showed strong immune responses
Subscribe To Our Newsletter & Stay Updated
